報價延遲最少15分鐘:2026/04/17 20:57 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.2637 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.58/-0.37
|
|
企業價值
6.71M
|
| 資產負債 |
|
每股賬面淨值
0.01
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
359.70K
|
|
每股收益
0.01
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies. |
